<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "dabrafenib cap">
<dose><value>150</value>
<value>100</value>
<value>50</value>
<value>75</value>
</dose>
<route><value>PO</value>
</route>
<strength><value>50 mg</value>
<value>75 mg</value>
</strength>
<frequency><value>BID</value>
</frequency>
<instruction></instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population></Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Dose level reductions: First reduction: 100 mg PO BID. Second reduction: 75 mg PO BID. Third reduction: 50 mg PO BID. If unable to tolerate 50 mg BID, recommend discontinuing dabrafenib. In clinical studies, patients 65 years of age and older experienced more serious adverse effects when taking dabrafenib.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=7302</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=7303</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>